From September 8th to 9th, 2022, the Chem Outsourcing Conference for Pharmaceutical Professionals (hereinafter referred to as "Chem Outsourcing Conference") was held successfully in New Jersey, US. As the largest API and pharmaceutical ingredients exhibition, the Chem Outsourcing Conference has attracted about 700 to 800 customers, project personnel, execution managers and business developers from pharmaceutical, biotechnology, chemical and chemical service industries in 30 countries. Laviana Pharma, as a technology-driven, innovative pharmaceutical contract development and manufacturing organization (CDMO), was invited to attend the conference.
The topic for this conference is API development supply chain, including raw materials, RSM, catalysts, drug discovery, process and chemical development, analysis, QA/QC, intermediates, branded and non-branded small molecule APIs and the commercial manufacturing of pharmaceutical products, so as to create a communication platform for the executive "buyers" of the pharmaceutical companies and consulting firms or "customers".
With the rapid development of the global pharmaceutical market, Laviana Pharma continues to invest in the enhancement of R&D and production capacity, accelerating the construction of the GMP production base in Cangzhou and launching the production base project in Anhui to further improve the comprehensive service capacity. Due to its investment in R&D and production, Laviana Pharma maintains its growth and vitality in the competitive environment, and has developed into a player widely known and praised by industry insiders.
Following the corporate culture of "People-oriented, Science-driven, Teamwork, Customer First and Pursuit of Excellence", Laviana Pharma actively explores and extends services to the downstream industry value chain. By building a world-leading platform for innovative process research and manufacture outsourcing to accelerate global pharmaceutical innovation, we provide more one-stop comprehensive services for domestic and foreign innovative pharmaceutical companies.